Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

7,167.00GBp
20 Sep 2019
Change (% chg)

40.00 (+0.56%)
Prev Close
7,127.00
Open
7,089.00
Day's High
7,242.00
Day's Low
7,066.00
Volume
4,510,193
Avg. Vol
1,790,179
52-wk High
7,583.00
52-wk Low
5,312.00

Select another date:

Tue, Sep 17 2019

Photo

AstraZeneca diabetes drug granted fast track status for heart failure treatment

AstraZeneca's diabetes drug, Farxiga, has been granted fast track designation by U.S. regulators for the treatment of heart failure, boosting prospects of wider use of the drug and putting it ahead of rivals.

AstraZeneca diabetes drug granted fast track status for heart failure treatment

AstraZeneca's diabetes drug, Farxiga, has been granted fast track designation by U.S. regulators for the treatment of heart failure, boosting prospects of wider use of the drug and putting it ahead of rivals.

UPDATE 1-AstraZeneca diabetes drug granted fast track status for heart failure treatment

Sept 16 AstraZeneca's diabetes drug, Farxiga, has been granted fast track designation by U.S. regulators for the treatment of heart failure, boosting prospects of wider use of the drug and putting it ahead of rivals.

AstraZeneca's Farxiga granted fast track status for heart failure treatment

Sept 16 AstraZeneca Plc said on Monday the U.S. Food and Drug Administration (FDA) had granted fast track designation for the development of its diabetes drug Farxiga to reduce the risk of deadly heart attacks in some patients.

CORRECTED-AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer

FRANKFURT, Sept 9 AstraZeneca's cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs.

AstraZeneca's Tagrisso helps lung cancer patients live longer: study

(Corrects Aug. 9 story to show study points to overall survival and not progression free survival in first paragraph)

CORRECTED-UPDATE 1-AstraZeneca's Tagrisso helps lung cancer patients live longer- study (Aug. 9)

Sept 4 AstraZeneca Plc said on Friday a late-stage study showed its top-selling drug, Tagrisso, had significantly helped patients with a type of lung cancer live longer.

CORRECTED-UPDATE 1-AstraZeneca's Tagrisso helps lung cancer patients live longer- study (Aug. 9)

Aug 9 AstraZeneca Plc said on Friday a late-stage study showed its top-selling drug, Tagrisso, had significantly helped patients with a type of lung cancer live longer.

AstraZeneca's Tagrisso gets China OK for type of lung cancer

AstraZeneca Plc said on Wednesday it had received marketing authorization from China's National Medical Products Administration for its top-selling drug, Tagrisso, to treat adults with a form of lung cancer.

CORRECTED-AstraZeneca's Tagrisso gets China OK for type of lung cancer

Sept 4 AstraZeneca Plc said on Wednesday it had received marketing authorisation from China's National Medical Products Administration for its top-selling drug, Tagrisso, to treat adults with a form of lung cancer.

Select another date: